Cipla, a global pharmaceutical company, has signed a non-exclusive
licensing agreement with Gilead Sciences, Inc. for manufacturing and
distribution of Sofosbuvir mono, Ledipasvir mono, the fixed-dose
combination of Ledipasvir/Sofosbuvir with each other and the combination
of Sofosbuvir or Ledipasvir with other active substances, for the
treatment of Hepatitis C Real Time News & Trading Trends Keep Liking Epic Research Private Limited
Facebook – Twitter – YouTube – Pinterest –Linkedin - Google+
For more information ✆ – 0731-6642300 or Visit http://www.epicresearch.co
No comments:
Post a Comment